GISTs and other cancers expressing un-mutated, wild-type KIT-RTKs, as well as those possessing exon 11, exon 9, and other less common activating mutations, can be inhibited with the KIT proto-oncogene receptor tyrosine kinases (KIT-TKIs) imatinib and ripretinib. This evidence concerns the gene KIT and cancer.